![]() |
市場調查報告書
商品編碼
1301673
生長激素市場 - 按產品、應用、配銷通路及全球預測,2023-2032年Growth Hormone Market - By Product, Application, Distribution Channel, & Global Forecast, 2023 - 2032 |
到2032年,全球生長激素市場規模將明顯擴大。生長激素療法在兒科病人中的應用不斷增加,促進了行業成長。這一人口群體中生長激素疾病的全球負擔增加了對生長激素療法的需求。此外,診斷能力的進步和醫護人員意識的提高使人們更早地發現了兒科病人的生長相關疾病,能夠及時用生長激素療法進行干涉。
此外,在該領域經營的行業參與者強調合併和收購戰略,以保持其行業地位。 2023年6月,美國製藥公司Eli Lily And Company宣布有意收購Sigilon,這是一家為急性和慢性疾病患者開發功能治療的生物製藥公司。
整個生長激素市場根據產品、應用、配銷通路和地區進行分類。
基於產品,來自溶劑部分的生長激素行業將在2023年至2032年紀錄顯著的成長。生長激素溶劑的易於管理和與不同配方的兼容性有利於其採用。生長激素溶劑的使用有助於提高患者對治療方案的依從性。透過簡化重組過程和盡量減少注射過程中的不適,病人可能會發現更容易和更方便地堅持他們規定的生長激素治療。
基於應用,從2023年到2032年,透納症候群領域的行業佔有率將以6.5%的年複合成長率成長,這是因為生長激素在解決透納症候群患者面臨的生長和發育挑戰方面具有顯著療效。生長激素療法在改善身高、骨密度、身體成分和整體生活品質方面有明顯的好處。隨著人們對透納症候群及其影響有了更多的認知,對生長激素等有效干涉措施的需求繼續增加,為個人實現最佳生長和充分發揮潛力提供了希望和機會。
基於配銷通路,零售藥店部分的行業價值將在2032年之前取得顯著收益。各種的藥物容易獲得,增加了病人對零售藥店的偏好。此外,這些設施直接向病人提供診斷方案、特殊餵養方案和藥物。他們經常提供教育資源和材料,以促進病人的健康和福祉。他們可以提供有關各種健康狀況、預防性護理和生活方式調整的資訊。
從區域角度看,歐洲生長激素市場規模到2032年將達到17億美元以上。生長激素缺乏症的發病率激增,增加了歐洲對生長激素療法的需求。該地區的成長也可歸因於不斷上升的數位化,加上諾華公司、Ferring BV等行業參與者的強大存在,致力於產品創新。
Global Growth Hormone Market size will expand significantly through 2032. Growing applications of growth hormone therapy in pediatric patients are contributing to industry growth. The global burden of growth hormone disorders in this demographic has increased the need for growth hormone therapies. Moreover, the advancements in diagnostic capabilities and rising awareness among healthcare professionals have led to earlier detection of growth-related disorders in pediatric patients, enabling timely intervention with growth hormone therapy.
Furthermore, industry players operating in the field are emphasizing mergers and acquisition strategies to retain their industry standing. In June 2023, Eli Lily And Company, an American pharmaceutical company, announced its intent to acquire Sigilon, a biopharmaceutical company that develops functional cures for patients with acute and chronic disorders.
The overall growth hormone market is classified based on product, application, distribution channel, and region.
Based on the product, the growth hormone industry from the solvent segment will record notable growth from 2023 to 2032. The ease of administration and compatibility of growth hormone solvents with different formulation favors its adoption. The use of growth hormone solvents can contribute to improved patient compliance with treatment regimens. By simplifying the reconstitution process and minimizing discomfort during the injection, patients may find it easier and more convenient to adhere to their prescribed growth hormone therapy.
Based on the application, industry share from the Turner syndrome segment will grow at a 6.5% CAGR from 2023 to 2032 due to the remarkable efficacy of growth hormones in addressing the growth and development challenges faced by individuals with Turner syndrome. Growth hormone therapy depicts notable benefits in improving height, bone density, body composition, and overall quality of life. As more awareness is raised about Turner syndrome and its impact, the need for effective interventions like growth hormones continues to increase, providing hope and opportunities for individuals to achieve optimal growth and reach their full potential.
Based on the distribution channel, industry value from the retail pharmacy segment will register significant gains through 2032. The easy availability of a wide range of medications has increased patient preference for retail pharmacies. Moreover, these facilities offer diagnostic solutions, special feeding solutions, and medications directly to patients. They often offer educational resources and materials to promote patient health and well-being. They may provide information on various health conditions, preventive care, and lifestyle modifications.
From the regional perspective, Europe growth hormone market size will reach over USD 1.7 billion by 2032. The surging prevalence of growth hormone deficiency disorders has increased the demand for growth hormone therapies in Europe. The regional growth can also be attributed to rising digitalization coupled with a robust presence of industry players such as Novartis AG, Ferring B.V., and others, focusing on product innovations.